Lyme Disease Vaccine: Pfizer’s VLA15 Trial

Lyme disease cases are rising globally, leaving many people searching for better protection than bug spray and long socks. For the first time in over 20 years, a new vaccine candidate is making significant progress toward FDA approval. Pfizer and French biotech company Valneva are currently conducting late-stage clinical trials for VLA15, a vaccine designed to prevent Lyme disease in both adults and children.

Understanding the VLA15 Vaccine

VLA15 is a protein subunit vaccine. This is a traditional type of vaccine technology, similar to the shots used for Hepatitis B or Whooping Cough. It works by targeting the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that causes Lyme disease.

The mechanism is unique compared to other vaccines. When an infected tick bites a vaccinated person, the antibodies in the person’s blood enter the tick’s gut during feeding. These antibodies neutralize the bacteria inside the tick before it can travel into the human bloodstream. Essentially, the vaccine stops the infection at the source.

Pfizer and Valneva have designed VLA15 to be “multivalent.” This means it targets six different serotypes (variations) of the OspA protein. These six types are the most common strains found in North America and Europe, making the vaccine a viable option for international travelers and residents of endemic regions.

Inside the Phase 3 VALOR Trial

The current study is technically known as the “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) trial. This is a randomized, placebo-controlled, Phase 3 study. Phase 3 is the final step before a company can apply for regulatory approval.

Trial Goals and Participants

The primary goal of the VALOR trial is to verify that VLA15 is safe and effective at preventing laboratory-confirmed Lyme disease. The study includes participants aged 5 years and older. This inclusion of children is critical, as data from the CDC shows that children between the ages of 5 and 9 are at the highest risk for Lyme disease infection.

Locations and Logistics

The trial is taking place in areas where Lyme disease is highly endemic (common). This includes sites across the Northeast United States, as well as locations in:

  • Finland
  • Germany
  • The Netherlands
  • Poland
  • Sweden

Participants in the trial receive a three-dose primary series followed by a booster dose roughly one year later.

Trial Setbacks and Adjustments

It is important to note a specific hurdle the trial faced in early 2023. Pfizer had to discontinue about half of the U.S. participants from the study. This was not due to safety concerns with the vaccine. Instead, it was due to violations of Good Clinical Practice (GCP) by a third-party clinical trial site operator called Care Access.

Despite this administrative setback, the trial continued with the remaining thousands of participants. Pfizer and Valneva have stated that the remaining data should still be sufficient to seek approval.

Why This Trial Matters Now

The medical community has not had a Lyme disease vaccine since 2002. The previous vaccine, LYMERix by SmithKline Beecham (now GSK), was withdrawn from the market. While LYMERix was effective, it faced low consumer demand and unproven media reports regarding side effects (such as arthritis) that hurt sales.

Since 2002, the landscape of tick-borne illness has changed drastically:

  • Rising Cases: The CDC estimates that approximately 476,000 people are diagnosed and treated for Lyme disease annually in the United States.
  • Climate Factors: Warmer winters are allowing ticks to expand their territory further north and remain active for longer periods.
  • Antibiotic Limitations: While antibiotics like Doxycycline treat early infections effectively, undiagnosed or late-stage Lyme can cause persistent, debilitating symptoms. Prevention is widely viewed as a superior strategy to treatment.

Potential Release Timeline

If the VALOR trial concludes successfully, Pfizer and Valneva plan to submit a Biologics License Application to the FDA and a Marketing Authorization Application to the European Medicines Agency (EMA).

Based on current trial schedules, the companies are targeting a potential regulatory submission in 2025. If the regulatory agencies prioritize the review, the vaccine could potentially be available to the public by 2026. This timeline depends heavily on the final data analysis showing strong efficacy and a clean safety profile.

Alternative Preventative Research

While VLA15 is the frontrunner, it is not the only project in the works. Other institutions are looking at different ways to stop the disease.

MassBiologics and Lyme PrEP

Researchers at the University of Massachusetts Chan Medical School (MassBiologics) are developing a method called Lyme PrEP (Pre-Exposure Prophylaxis). This is not a traditional vaccine. Instead, it is a monoclonal antibody shot that delivers immediate immunity.

While a vaccine requires your body to learn how to make antibodies (taking weeks or months), the Lyme PrEP shot provides the antibodies directly. It is designed to be a seasonal shot that you would get at the start of tick season.

mRNA Technology

Following the success of COVID-19 vaccines, researchers at Yale University are exploring mRNA technology for Lyme. Their experimental approach targets the tick’s saliva rather than the bacteria. The goal is to cause an immediate skin reaction (like a mosquito bite itch) that alerts the human to pull the tick off before the bacteria can transmit, which usually takes 24 to 48 hours. However, this is still in early research stages compared to Pfizer’s VLA15.

Frequently Asked Questions

Is the VLA15 vaccine available now? No. It is currently in Phase 3 clinical trials. It is not yet approved by the FDA or available at doctors’ offices.

Will the vaccine cure Lyme disease if I already have it? No. VLA15 is a preventative vaccine. It is designed to stop you from getting infected. It is not a treatment for an active or chronic infection.

How many shots will the vaccine require? The current trial protocol tests a three-dose primary series (Month 0, Month 2, and Month 5-9), followed by a booster dose one year later. It is possible that, like the flu shot, annual or periodic boosters might be required to maintain immunity.

Is the vaccine safe for children? The Phase 2 studies showed that the vaccine was generally safe and well-tolerated in both adults and children, with antibody responses actually being stronger in children. The Phase 3 trial explicitly includes children aged 5 and up to ensure safety for this high-risk group.